Evidence map›Paper›PMID 41765064›Full record

ArticleActa biomaterialia2026

Recapitulating patient-to-patient colorectal cancer tumor heterogeneity using patient-derived xenograft cells in an engineered tissue model.

Iman Hassani, Benjamin Anbiah, Yuan Tian, Bulbul Ahmed, William J Van Der Pol, Elliot J Lefkowitz, Peyton Kuhlers, Nicole L Habbit, Martin J Heslin, Michael W Greene and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta biomaterialia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Iman HassaniDepartment of Chemical Engineering, Auburn University, Auburn, AL 36849, USA; Department of Chemical Engineering, Tuskegee University, Tuskegee, AL 36088, USA.
Benjamin AnbiahDepartment of Chemical Engineering, Auburn University, Auburn, AL 36849, USA.
Yuan TianDepartment of Chemical Engineering, Auburn University, Auburn, AL 36849, USA.
Bulbul AhmedDepartment of Nutritional Sciences, Auburn University, Auburn, AL 36849, USA.
William J Van Der PolCenter for Clinical and Translational Science, University of Alabama at Birmingham, Birmingham, AL 35233, United States.
Elliot J LefkowitzCenter for Clinical and Translational Science, University of Alabama at Birmingham, Birmingham, AL 35233, United States; Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35233, United States.
Peyton KuhlersDepartment of Nutritional Sciences, Auburn University, Auburn, AL 36849, USA.
Nicole L HabbitDepartment of Chemical Engineering, Auburn University, Auburn, AL 36849, USA.
Martin J HeslinDepartment of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, United States.
Michael W GreeneDepartment of Nutritional Sciences, Auburn University, Auburn, AL 36849, USA. Electronic address: mwgreene@auburn.edu.
Elizabeth A LipkeDepartment of Chemical Engineering, Auburn University, Auburn, AL 36849, USA. Electronic address: elipke@auburn.edu.

Funding

UAB Center for Clinical and Translational Science (CCTS)UL1TR001417 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KIMBERLY, ROBERT P. · 2015 to 2018
$31.4M
Engineered Colon Cancer Tissue to Examine the Role of the Obese Microenvironment in Tumor AggressivenessR01CA267170 · NCI · AUBURN UNIVERSITY AT AUBURN · PI Michael W Greene, Elizabeth A Lipke · 2022 to 2026
$2.6M
NCATS NIH HHS UL1 TR001417NCI NIH HHS R01 CA267170
6 · The paper itself

Abstract

Establishing in vitro cancer models that more closely recapitulate patient tumor microenvironmental heterogeneity, including variations in stromal cells and mechanical properties that influence colorectal cancer (CRC) progression, is crucial for advancing CRC research. This study evaluated the ability of 3D engineered CRC-PDX (3D-eCRC-PDX) tissues to recapitulate the heterogeneity found between patient-derived xenograft (PDX) tumors from three CRC patients (stage II, III-B, and IV). To form the 3D-eCRC-PDX tissues, CRC-PDX tumor cells were encapsulated in PEG-fibrinogen hydrogels and maintained for 29 days in vitro. 3D-eCRC-PDX tissues recapitulated key patient-specific tumor characteristics. During long-term culture, 3D-eCRC-PDX tissues mimicked the patient-specific growth rates of the originating CRC-PDX tumors. Importantly, tumor cellular subpopulations, including the ratio of human cancer cells to mouse stromal cells and the ratios of proliferative human cancer cells and CK20

Indexed as

Colorectal NeoplasmsTissue EngineeringAnimalsCell Line, TumorFibrinogenHeterograftsHumansHydrogelsMiceStromal CellsTumor MicroenvironmentFibrinogenHydrogelsCancer tissue engineeringColon cancerOrganoidPDXStiffnessTumor microenvironment

Identifiers

PMID41765064
PMCPMC13310180

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.